Extract

The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.

Inclusion criteria

• Breast Neoplasms ,Neoplasms, Hormone-Dependent

Country

• Bulgaria
• Romania
• Russian Federation
• Ukraine
• United States

Links

• nct
• ictrp